Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Investigation Report on China's Ranibizumab Market, 2012-2019 | ||
By: PR Newswire Association LLC. - 28 Aug 2015 | Back to overview list |
|
DUBLIN, Aug. 28, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sqh7xc/investigation) has announced the addition of the "Investigation Report on China's Ranibizumab Market, 2012-2019" report to their offering. Developed by Novartis, ranibizumab was approved by CFDA to treat wet age- related macular degeneration (AMD) in 2012. Currently, only Lucentis, a product of Novartis, is available in the Chinese market. However, in Dec. 2013, as the first self- developed drug for the treatment of wet AMD in China, conbercept ophthalmic injection got CFDA's approval. - market size of ranibizumab in China Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net SOURCE Research and Markets |
||
|
||
Copyright 2015 PR Newswire Association LLC. | Back to overview list |